Based on work by Schlenk et al. [1], the data has been shown that mutations of FMS related tyrosine kinase 3 (FLT3)-internal tandem duplications (ITDs), nucleophosmin1 (NPM1) and CCAAT/enhancer binding protein α gene (CEBPA) can indicate the prognosis of disease in normal karyotype AML. This evidence concerns the gene CEBPA and acute myeloid leukemia.